![Iressa (gefitinib) has been approved by the U.S. Food and Drug Administration to treat patients with metastatic non-small-cell lung cancer with a specific genetic mutation (epidermal growth factor receptor [EGFR]). A just-approved companion diagnostic test can identify patients who could benefit from this new use.](https://www.ehealth-news.com/wp-content/uploads/2016/01/fdalogo-6-180x84.jpg "FDA Approves Iressa for EGFR+ Metastatic Lung Cancer")
FDA Approves Iressa for EGFR+ Metastatic Lung Cancer
New companion diagnostic kit can identify candidates
Farm-Related Immunoregulation Tied to Dendritic Cell Subset
Lower levels of circulating myeloid dendritic cell subtype 2 in children who live on farms
Specific Biomarkers ID Cardiac Dysfunction, Mortality Risk in HIV
ST2 and GDF-15 linked to cardiovascular dysfunction and all-cause mortality in HIV-infected
IGF2 Variant Affects Prenatal and Postnatal Growth
Severe growth restriction for family members who inherit the variant through paternal transmission
Herpes Simplex Virus Can Mimic Premature Rupture of Membranes
Case vignette describes woman with leakage of clear fluid, despite normal amniotic fluid volume
Exotic Squirrels Transmit Deadly Virus to Breeders in Germany
Breeders diagnosed with encephalitis and died within two to four months of symptom onset
Pockets of U.S. Have Excessive Colorectal Cancer Mortality
Areas include parts of the Mississippi Delta, Appalachia, and eastern Virginia
Genetic Mutations May Impact Outcomes in Aplastic Anemia
Genetic evaluation may help predict prognosis in aplastic anemia
Mortality Rates Declining for Many Cancers
Rates predicted to meet Healthy People 2020 targets for breast, lung, prostate cancers
Weight Loss + Vitamin D3 Cuts IL-6 in Postmenopausal Women
Reduction in inflammatory biomarkers among women with BMI >25 kg/m², low serum 25(OH)D
